|Bid||1.25 x 1300|
|Ask||1.26 x 1000|
|Day's Range||1.20 - 1.27|
|52 Week Range||1.02 - 27.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.14|
vTv Therapeutics Inc (NASDAQ: VTVT ) shares have outperformed Axovant Sciences Ltd (NASDAQ: AXON ) shares by 63 percent since Chardan recommended owning the former over the latter in January 2016. The ...
Law Offices of Howard G. Smith commences an investigation on behalf of Axovant Sciences Ltd. investors concerning the Company and its officers’ possible violations of federal securities laws.
Axovant Chief Operating Officer Marion McCourt and three directors on the company's board also stepped down. The departures come after Axovant stopped developing its lead drug, intepirdine, following the failure of two trials testing it as a treatment for Alzheimer's disease and dementia. "There is plenty of work to be done," incoming Axovant CEO Pavan Cheruvu said on a call with analysts.
Axovant Sciences Ltd (NASDAQ: AXON )'s announcement this week that its lead drug candidate intepirdine failed in a late-stage trial comes after the stock lost 90 percent of its value over the past three ...
Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.
Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
Roivant-backed health care technology company Datavant – formed late last year – has landed its first academic partner in Duke Clinical Research Institute (DCRI). Since the rollout of Datavant – on the heels of Roivant landing a $1.1 billion equity investment led by SoftBank Vision Fund – Datavant has integrated 150 datasets, aimed at using artificial intelligence to improve the time and success of clinical trials as well as their costs. "As I was founding Datavant, one of the first members of our advisory board was Frank Rockhold, a tireless advocate of clinical data sharing and a professor of biostatistics and bioinformatics at DCRI. Soon after meeting with other members of the DCRI leadership we each recognized the strong fit between our organizations and the potential for a partnership that would transform the drug development process,” Travis May, president and co-founder of Datavant, said in an email.